Profile Picture
Rewards
  • All
  • Images
  • Videos
  • Maps
  • News
  • Shopping
  • More
    • Flights
    • Travel
    • Hotels
    • Real Estate
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Politics
  • Business

Trending on Bing

45-day funding bill OK'd
100,000+ Armenians fled
Staff pay & title changes
Bowman pulls fire alarm
‘One day at a time'
Addresses Tupac's murder
Nobel Prize key details
Suggests shooting shoplifters
Clippard retires from MLB
Sued for racial discrimination
Bed bug infestation in Paris
Becky G embraces heritage
Feinstein's LGBTQ+ history
Onewheel recall
Celtics sign DJ Steward
Fed agency sues Chipotle
U2 opening concert in Vegas
To fix overheating issues
Flying Scotsman train crash
Ryder Cup record
Raiders release Jones
SpaceX adds 22 satellites
Illinois semi-truck crash
Renaissance tour movie
Locked woman in a cell?
Tests COVID positive
'I don't know who we are'
Parasite found in lake
Body found on 5 Freeway
Student loan restart
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days
  • Best match
    • Most recent
162,000 results
2d
First FDA Approved Drug to Slow Alzheimer’s
Joan was diagnosed with early-stage Alzheimer’s disease. There was nothing doctors could do. But now, a recently FDA-approved ...
朝日新聞社12d
Alzheimer’s drug Leqembi has full FDA approval
Alzheimer’s drug Leqembi has full FDA approval THE ASSOCIATED PRESS July 7, 2023 at 07:30 JST Share Tweet list Print This image provided by Eisai in January 2023 shows vials and packaging for ...
10don MSN
Medical Moment: FDA approves first-ever drug to slow Alzheimer’s
There is no cure yet, but now, a newly FDA-approved drug is helping to slow its progression before it’s too late.
2d
FDA advisers vote against experimental ALS treatment pushed by patients
The panel of Food and Drug Administration experts voted 17-1 that drugmaker Brainstorm’s stem cell-based treatment has not ...
Forbes19d
What To Know About The Alzheimer’s Drug Leqembi
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.
Washington Examiner29d
FDA needs to let go of its risk-averse regulatory model
The FDA also gave full approval to a drug called Leqembi, which slowed Alzheimer’s patients’ functional and cognitive decline by 27% over 18 months, according to trial data.
4d
After US approval, Japan approves Leqembi, its first Alzheimer's drug
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.
The Financial Times27d
Vivek Ramaswamy’s FDA ‘corruption’ claims disavowed by Roivant
We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...
1don MSN
FDA wants to regulate thousands of lab tests that have long skirted oversight
The Food and Drug Administration says it plans to begin regulating laboratory-based medical tests. It's a multibillion-dollar industry that regulators say poses a growing risk to patients.
朝日新聞社3d
Alzheimer’s drug lecanemab set to soon be approved for use in Japan
A medication that could help treat early stages of Alzheimer's disease is on track to be approved for manufacturing and sales in Japan after being endorsed by a health ministry expert panel on ...
WISH-TV
3d
Health Spotlight: First FDA-approved drug to slow Alzheimer’s
More than 6,000,000 Americans are living with Alzheimer's disease – it slowly steals your memories and takes away your mind ...
4d
After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results
© 2023 Microsoft
  • Privacy and Cookies
  • Legal
  • Advertise
  • About our ads
  • Help
  • Feedback
  • Your Privacy Choices